123 related articles for article (PubMed ID: 16208219)
1. [Prevention of proliferative vitreoretinopathy using 5-FU heparin: clinical tolerance and efficacy].
Scheer S; Morel C; Poisson F; Bonnel S; Touzeau O; Sahel JA; Laroche L
J Fr Ophtalmol; 2005 Sep; 28(7):701-6. PubMed ID: 16208219
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy : Results from a randomized, double-blind, controlled clinical trial.
Asaria RH; Kon CH; Bunce C; Charteris DG; Wong D; Khaw PT; Aylward GW
Ophthalmology; 2001 Jul; 108(7):1179-83. PubMed ID: 11425671
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal 5-Fluorouracil and Heparin to Prevent Proliferative Vitreoretinopathy: Results from a Randomized Clinical Trial.
Schaub F; Schiller P; Hoerster R; Kraus D; Holz FG; Guthoff R; Agostini H; Spitzer MS; Wiedemann P; Lommatzsch A; Boden KT; Dimopoulos S; Bemme S; Tamm S; Maier M; Roider J; Enders P; Altay L; Fauser S; Kirchhof B;
Ophthalmology; 2022 Oct; 129(10):1129-1141. PubMed ID: 35680097
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy in high-risk patients with retinal detachment: study protocol for a randomized controlled trial.
Schaub F; Hoerster R; Schiller P; Felsch M; Kraus D; Zarrouk M; Kirchhof B; Fauser S
Trials; 2018 Jul; 19(1):384. PubMed ID: 30012187
[TBL] [Abstract][Full Text] [Related]
5. Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy?
Williams RG; Chang S; Comaratta MR; Simoni G
Graefes Arch Clin Exp Ophthalmol; 1996 Aug; 234(8):496-503. PubMed ID: 8858355
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery.
Sundaram V; Barsam A; Virgili G
Cochrane Database Syst Rev; 2010 Jul; (7):CD006421. PubMed ID: 20614445
[TBL] [Abstract][Full Text] [Related]
7. Combined 5-fluorouracil, low-molecular-weight heparin, and silicone oil in the management of complicated retinal detachment with proliferative vitreoretinopathy grade C.
Garcia RA; Sanchez JG; Arevalo JF
Ophthalmic Surg Lasers Imaging; 2007; 38(4):276-82. PubMed ID: 17674917
[TBL] [Abstract][Full Text] [Related]
8. Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy.
Wickham L; Bunce C; Wong D; McGurn D; Charteris DG
Ophthalmology; 2007 Apr; 114(4):698-704. PubMed ID: 17398320
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy.
Charteris DG; Aylward GW; Wong D; Groenewald C; Asaria RH; Bunce C;
Ophthalmology; 2004 Dec; 111(12):2240-5. PubMed ID: 15582080
[TBL] [Abstract][Full Text] [Related]
10. Retinal detachment repair by vitrectomy: simplified formulae to estimate the risk of failure.
Wickham L; Bunce C; Wong D; Charteris DG
Br J Ophthalmol; 2011 Sep; 95(9):1239-44. PubMed ID: 21325394
[TBL] [Abstract][Full Text] [Related]
11. Effect of intraoperative 5-fluorouracil and low molecular weight heparin on the outcome of high-risk proliferative vitreoretinopathy.
Ganekal S; Dorairaj S
Saudi J Ophthalmol; 2014 Oct; 28(4):257-61. PubMed ID: 25473340
[TBL] [Abstract][Full Text] [Related]
12. Combined 5-Fluorouracil and Low Molecular Weight Heparin for the Prevention of Postoperative Proliferative Vitreoretinopathy in Patients With Retinal Detachment: A Meta-Analysis.
Chen C; Chen P; Liu X; Li H
Front Med (Lausanne); 2021; 8():790460. PubMed ID: 34917641
[No Abstract] [Full Text] [Related]
13. Preservation of anterior capsule during vitrectomy and lensectomy for retinal detachment with proliferative vitreoretinopathy.
MacCumber MW; Packo KH; Civantos JM; Greenberg JB
Ophthalmology; 2002 Feb; 109(2):329-33. PubMed ID: 11825819
[TBL] [Abstract][Full Text] [Related]
14. Surgical failure following primary retinal detachment surgery by vitrectomy: risk factors and functional outcomes.
Wickham L; Ho-Yen GO; Bunce C; Wong D; Charteris DG
Br J Ophthalmol; 2011 Sep; 95(9):1234-8. PubMed ID: 21156702
[TBL] [Abstract][Full Text] [Related]
15. Vitrectomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy: results of additional and long-term follow-up. Silicone Study report 11.
Abrams GW; Azen SP; McCuen BW; Flynn HW; Lai MY; Ryan SJ
Arch Ophthalmol; 1997 Mar; 115(3):335-44. PubMed ID: 9076205
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of surgery for retinal detachment associated with proliferative vitreoretinopathy using perfluoro-n-octane: a multicenter study.
Scott IU; Flynn HW; Murray TG; Feuer WJ;
Am J Ophthalmol; 2003 Sep; 136(3):454-63. PubMed ID: 12967798
[TBL] [Abstract][Full Text] [Related]
17. Shaken not stirred.
Sebag J
Ophthalmology; 2001 Jul; 108(7):1177-8. PubMed ID: 11425670
[No Abstract] [Full Text] [Related]
18. [Surgical treatment of rhegmatogenous retinal detachments with high risk of proliferative vitreoretinopathy].
Akhundova LA; Kasimov EM
Vestn Oftalmol; 2017; 133(3):51-57. PubMed ID: 28745657
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy.
Schiff WM; Hwang JC; Ober MD; Olson JL; Dhrami-Gavazi E; Barile GR; Chang S; Mandava N
Arch Ophthalmol; 2007 Sep; 125(9):1161-7. PubMed ID: 17846353
[TBL] [Abstract][Full Text] [Related]
20. Preoperative vitreous hemorrhage associated with rhegmatogenous retinal detachment: a risk factor for postoperative proliferative vitreoretinopathy?
Duquesne N; Bonnet M; Adeleine P
Graefes Arch Clin Exp Ophthalmol; 1996 Nov; 234(11):677-82. PubMed ID: 8950587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
